Alimera Sciences Announces ILUVIEN® now available in Ireland
September 12 2017 - 4:01PM
Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in the
commercialization and development of prescription ophthalmic
pharmaceuticals, today announced that ILUVIEN, its sustained
release intravitreal implant for the treatment of diabetic macular
edema (DME), is now available in Ireland through VHI Healthcare
Group, the leading Irish healthcare provider.
“Diabetes remains the most serious cause of severe vision loss
in people of working age in Ireland, and diabetic macular edema is
the cause in around 10% of those cases,” said Marie Hickey Dwyers,
former president of the Irish College of Ophthalmologists. “The
approval of ILUVIEN in Ireland is exciting news for all those
patients who are no longer responding to their first-line DME
treatment. The ILUVIEN implant could mean the difference between a
patient having increasingly deteriorating sight, and being able to
drive again. I look forward to having ILUVIEN as an option for my
patients.”
“In post-marketing studies in our European markets and the U.S.,
ILUVIEN has proven to be an effective, long-lasting treatment for
DME that decreases treatment burden. We are excited that DME
patients in Ireland will have access to this long-lasting treatment
that provides continuous daily micro-dosing for up to three years,”
said Dan Myers, Alimera’s CEO. “We are also proud to be working
with the largest Irish healthcare provider to open the gateway for
ILUVIEN in Ireland.”
About ILUVIEN
www.ILUVIEN.com
ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg is
a sustained release intravitreal implant indicated in the E.U. to
treat vision impairment associated with chronic DME considered
insufficiently responsive to available therapies. Each ILUVIEN
implant with its continuous microdosing is designed to release
submicrogram levels of fluocinolone acetonide, a corticosteroid,
for 36 months, enabling the physician to treat the disease
consistently every day.
About Diabetic Macular Edema (DME)
DME, the primary cause of vision loss associated with diabetic
retinopathy, is a disease affecting the macula, the part of the
retina responsible for central vision. When the blood vessel
leakage associated with diabetic retinopathy results in swelling of
the macula, the condition is called DME. The onset of DME is
painless and may go unreported by the patient until it manifests
with the blurring of central vision or acute vision loss. The
severity of this blurring may range from mild to profound loss of
vision. The Wisconsin Epidemiologic Study of Diabetic Retinopathy
found that over a 10-year period approximately 19% of people with
diabetes included in the study were diagnosed with DME. All people
with type 1 or type 2 diabetes are at risk of developing DME.
About VHI Healthcare Group
Since 1957, VHI has been helping people in Ireland to access the
best value, quality private healthcare through its extensive range
of diverse healthcare products and services. With one million
customers, they continue to be the market leader for health
insurance in Ireland. The brand promise - “When you need us, we're
there” - is true for practically every medical eventuality, whether
you need coverage for hospital treatment, daycare treatment,
day-to-day expenses, multi-trip travel insurance, expatriate
insurance, dental, walk‑in urgent care, medical screening,
occupational health, employee assistance programs or hospital in
the home services. Customers and their dependents are covered
individually, or through membership of one of more than 8,000
corporate and affinity group schemes countrywide. For more
information, visit https://www.vhi.ie/home.
About Alimera Sciences, Inc.
www.alimerasciences.com
Alimera, founded in June 2003, is a pharmaceutical company
that specializes in the commercialization and development of
prescription ophthalmic pharmaceuticals. Alimera is presently
focused on diseases affecting the back of the eye, or retina,
because these diseases are not well treated with current therapies
and will affect millions of people in our aging populations.
Alimera’s commitment to retina specialists and their patients is
manifest in Alimera’s product and development portfolio designed to
treat early- and late-stage diseases. For more information, please
visit www.alimerasciences.com.
Forward Looking Statements
This press release contains “forward-looking statements,” within
the meaning of the Private Securities Litigation Reform Act of
1995, regarding, among other things, the availability of ILUVIEN to
patients in Ireland. Such forward-looking statements are based on
current expectations and involve inherent risks and uncertainties,
including factors that could delay, divert or change any of them,
and could cause actual results to differ materially from those
projected in its forward-looking statements. Meaningful factors
which could cause actual results to differ include, but are not
limited to, the willingness of physicians in Ireland to accept
ILUVIEN for use with their DME patients, as well as the other
factors discussed in the “Risk Factors” and “Management’s
Discussion and Analysis of Financial Condition and Results of
Operations” sections of Alimera’s Annual Report on Form 10-K for
the year ended December 31, 2016 and Quarterly Report on Form
10-Q for the quarter ended June 30, 2017, which are on file
with the Securities and Exchange Commission (SEC) and
available on the SEC’s website at www.sec.gov.
Additional factors may be set forth in those sections of Alimera's
Quarterly Report on Form 10-Q for the quarter ending September 30,
2017, to be filed in the fourth quarter of 2017 with the SEC. In
addition to the risks described above and in Alimera’s Annual
Report on Form 10-K, Quarterly Reports on Form 10-Q, Current
Reports on Form 8-K and other filings with the SEC, other
unknown or unpredictable factors also could affect Alimera’s
results. There can be no assurance that the actual results or
developments anticipated by Alimera will be realized or, even if
substantially realized, that they will have the expected
consequences to, or effects on, Alimera. Therefore, no assurance
can be given that the outcomes stated in such forward-looking
statements and estimates will be achieved.
All forward-looking statements contained in this press release
are expressly qualified by the cautionary statements contained or
referred to herein. Alimera cautions investors not to rely too
heavily on the forward-looking statements Alimera makes or that are
made on its behalf. These forward-looking statements speak only as
of the date of this press release (unless another date is
indicated). Alimera undertakes no obligation, and specifically
declines any obligation, to publicly update or revise any such
forward-looking statements, whether as a result of new information,
future events or otherwise.
For press
inquiries:Katie Brazelfor Alimera Sciences
404-317-8361kbrazel@bellsouth.net |
For investor inquiries:CG Capitalfor Alimera
Sciences 877-889-1972 investorrelations@cg.capital |
Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart
From Apr 2023 to Apr 2024